Modelling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Thailand

References

• World Health Organization. WHO coronavirus (COVID-19) dashboard 2023. [cited 2023 May 4]. Available from: https://covid19.who.int/table
   Google Scholar
• Meadows AJ, Oppenheim B, Guerrero J, et al. Estimating infectious disease underreporting at the country level: a model and application to the COVID-19 pandemic. 2020. Available at SSRN 3706059. doi: 10.2139/ssrn.3706059
   Google Scholar
• Duangchaemkarn K, Boonchieng W, Wiwatanadate P, et al. SARIMA model forecasting performance of the COVID-19 daily statistics in Thailand during the Omicron variant epidemic. Healthcare. 2022;10(7):1310. editorsMDPI. doi: 10.3390/healthcare10071310
   Web of Science ®Google Scholar
• Suphanchaimat R, Teekasap P, Nittayasoot N, et al. Forecasted trends of the new COVID-19 epidemic due to the Omicron variant in Thailand, 2022. Vaccines. 2022;10(7):1024. doi: 10.3390/vaccines10071024
   Web of Science ®Google Scholar
• Nittayasoot N, Suphanchaimat R, Thammawijaya P, et al. Real-World effectiveness of COVID-19 vaccines against severe outcomes during the period of Omicron predominance in Thailand: a test-negative nationwide case–Control study. Vaccines. 2022;10(12):2123. doi: 10.3390/vaccines10122123
   Web of Science ®Google Scholar
• Intawong K, Chariyalertsak S, Chalom K, et al. Waning vaccine response to severe COVID-19 outcomes during omicron predominance in Thailand. PLoS One. 2023;18(5):e0284130. doi: 10.1371/journal.pone.0284130
   PubMed Web of Science ®Google Scholar
• Grewal R, Nguyen L, Buchan SA, et al. Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes. Nat Commun. 2023;14(1):1273. doi: 10.1038/s41467-023-36566-1
   PubMed Web of Science ®Google Scholar
• Collie S, Nayager J, Bamford L, et al. Effectiveness and durability of the BNT162b2 vaccine against omicron sublineages in South Africa. N Engl J Med. 2022;387(14):1332–1333. doi: 10.1056/NEJMc2210093
   PubMed Web of Science ®Google Scholar
• Kirsebom F, Andrews N, Stowe J, et al. Effectiveness of the COVID-19 vaccines against severe disease with Omicron sub-lineages BA. 4 and BA. 5 in England. Lancet Reg Health- Europe. 2022;23:100537 .
   PubMedGoogle Scholar
• Rosenblum HG, Wallace M, Godfrey M, et al. Interim recommendations from the advisory committee on immunization practices for the use of bivalent booster doses of COVID-19 vaccines—United States, October 2022. Morbidity Mortality Weekly Rep. 2022;71(45):1436–1441. doi: 10.15585/mmwr.mm7145a2
   PubMed Web of Science ®Google Scholar
• Sirison K, Nittayasoot N, Techasuwanna R, et al. Cost-effectiveness analysis of COVID-19 vaccine booster dose in the Thai setting during the period of Omicron variant predominance. Trop Med Infect Dis. 2023 Jan 30;8(2):91. doi: 10.3390/tropicalmed8020091
   PubMedGoogle Scholar
• Wang Y, Luangasanatip N, Pan-Ngum W, et al. Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic. Eur J Health Econ. 2023 Jul;24(5):735–748. doi: 10.1007/s10198-022-01505-2
   PubMed Web of Science ®Google Scholar
• Di Fusco M, Marczell K, Deger KA, et al. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States. J Med Econ. 2022;25(1):605–617. doi: 10.1080/13696998.2022.2071427
   PubMed Web of Science ®Google Scholar
• Cooper I, Mondal A, Antonopoulos CG. A SIR model assumption for the spread of COVID-19 in different communities. Chaos, Solitons & Fractals. 2020 Oct;139:110057. doi: 10.1016/j.chaos.2020.110057
   PubMed Web of Science ®Google Scholar
• Amaro JE, Dudouet J, Orce JN. Global analysis of the COVID-19 pandemic using simple epidemiological models. Appl Math Modell. 2021;90:995–1008. doi: 10.1016/j.apm.2020.10.019
   Web of Science ®Google Scholar
• Calafiore GC, Novara C, Possieri C. A time-varying SIRD model for the COVID-19 contagion in Italy. Annu Rev Control. 2020;50:361–372. doi: 10.1016/j.arcontrol.2020.10.005
   PubMed Web of Science ®Google Scholar
• Ndaïrou F, Area I, Nieto JJ, et al. Mathematical modeling of COVID-19 transmission dynamics with a case study of Wuhan. Chaos, Solitons & Fractals. 2020;135:109846. doi: 10.1016/j.chaos.2020.109846
   PubMed Web of Science ®Google Scholar
• Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force–7. Med Decis Mak. 2012;32(5):733–743. doi: 10.1177/0272989X12454579
   PubMed Web of Science ®Google Scholar
• National Statistical Office Thailand. Number of population by age, sex, region and province 2021. Available from: http://statbbi.nso.go.th/staticreport/page/sector/en/01.aspx
   Google Scholar
• Centers for Disease and Control Prevention. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals 2023. [ updated 2023 Feb 9; cited 2023 Jul 31]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html
   Google Scholar
• Pothirat C, Chaiwong W, Phetsuk N, et al. A comparative study of COPD burden between urban vs rural communities in northern Thailand. Int J Chron Obstruct Pulmon Dis. 2015;10:1035–1042.
   PubMed Web of Science ®Google Scholar
• Regional COPD Working Group. COPD prevalence in 12 Asia–Pacific countries and regions: projections based on the COPD prevalence estimation model. Respirology. 2003;8(2):192–198. doi: 10.1046/j.1440-1843.2003.00460.x
   PubMed Web of Science ®Google Scholar
• Ingsathit A, Thakkinstian A, Chaiprasert A, et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dialysis Transplantation. 2010;25(5):1567–1575. doi: 10.1093/ndt/gfp669
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cancer Thailand 2020 country profile 2020. Available from: https://www.who.int/publications/m/item/cancer-tha-2020
   Google Scholar
• Tatsanavivat P, Klungboonkrong V, Chirawatkul A, et al. Prevalence of coronary heart disease and major cardiovascular risk factors in Thailand. Int J Epidemiol. 1998;27(3):405–409. doi: 10.1093/ije/27.3.405
   PubMed Web of Science ®Google Scholar
• Global Asthma Network. The Global asthma report 2022: Thailand 2022 [cited 2023 Feb 1]. Available from: http://globalasthmareport.org/regions/thailand.php
   Google Scholar
• Macrotrends. Thailand smoking rate 2000-2023. [cited 2023 Feb 1]. Available from: https://www.macrotrends.net/countries/THA/thailand/smoking-rate-statistics#:~:text=1%20Thailand%20smoking%20rate%20for%202020%20was%2022.10%25%2C,2015%20was%2024.10%25%2C%20a%202.2%25%20decline%20from%202010
   Google Scholar
• CoVariants. Overview of variants in countries. [ updated 2023 Sep 5; cited 2023]. Available from: https://covariants.org/per-country
   Google Scholar
• Ministry of Public Health of Thailand. COVID-19 situation updated Weekly 2023. Available from: https://covid19.ddc.moph.go.th/
   Google Scholar
• World Health Organization. WHO Thailand Weekly Situation Update No. 225. 2022. Available from: https://cdn.who.int/media/docs/default-source/searo/thailand/2022_03_02_tha-sitrep-225-covid-19.pdf?sfvrsn=32cca21b_5
   Google Scholar
• Tartof SY, Slezak JM, Puzniak L, et al. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA. 4 and BA. 5. Lancet Infect Dis. 2022;22(12):1663–1665. doi: 10.1016/S1473-3099(22)00692-2
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Puzniak L, et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study. Lancet Respir Med. 2022;10(7):689–699. doi: 10.1016/S2213-2600(22)00101-1
   PubMed Web of Science ®Google Scholar
• Arbel R, Peretz A, Sergienko R, et al. Effectiveness of the bivalent mRNA vaccine in preventing severe COVID-19 outcomes: an observational cohort study. 2023. Available at SSRN 4314067. doi: 10.2139/ssrn.4314067
   Google Scholar
• Link-Gelles R. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA. 5–and XBB/XBB. 1.5–related sublineages among immunocompetent adults—increasing community access to testing program, United States, December 2022–January 2023. MMWR Morb Mortal Wkly Rep. 2023;72.
   Web of Science ®Google Scholar
• Surie D, Bonnell L, Adams K, et al. Effectiveness of monovalent mRNA vaccines against COVID-19-Associated hospitalization among immunocompetent adults during BA.1/BA.2 and BA.4/BA.5 predominant periods of SARS-CoV-2 Omicron variant in the United States - IVY network, 18 States, December 26, 2021-August 31, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(42):1327–1334. doi: 10.15585/mmwr.mm7142a3
   PubMed Web of Science ®Google Scholar
• Surie D. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–associated hospitalization among immunocompetent adults aged≥ 65 years—IVY network, 18 States, September 8–November 30, 2022. MMWR Morb Mortal Wkly Rep. 2022;71.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. What is COVID-19 reinfection? 2022 [ updated 2023 Mar 15; cited 2022 Oct 30]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/your-health/reinfection.html
   Google Scholar
• Eythorsson E, Runolfsdottir HL, Ingvarsson RF, et al. Rate of SARS-CoV-2 reinfection during an omicron wave in Iceland. JAMA Netw Open. 2022;5(8):e2225320–e2225320. doi: 10.1001/jamanetworkopen.2022.25320
   PubMed Web of Science ®Google Scholar
• Shang W, Kang L, Cao G, et al. Percentage of asymptomatic infections among SARS-CoV-2 omicron variant-positive individuals: a systematic review and meta-analysis. Vaccines. 2022;10(7):1049. doi: 10.3390/vaccines10071049
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Estimated COVID-19 burden. 2022 [ updated 2022 Aug 12; cited 2023 Jan 19]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html
   Google Scholar
• Mattey‐Mora PP, Begle CA, Owusu CK, et al. Hospitalised versus outpatient COVID‐19 patients’ background characteristics and comorbidities: a systematic review and meta‐analysis. Rev Med Virol. 2022;32(3):e2306. doi: 10.1002/rmv.2306
   PubMed Web of Science ®Google Scholar
• Sim BLH, Chidambaram SK, Wong XC, et al. Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: a nationwide observational study. Lancet Reg Health-West Pac. 2020;4:100055. doi: 10.1016/j.lanwpc.2020.100055
   PubMedGoogle Scholar
• Surendra H, Elyazar IR, Djaafara BA, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: a hospital-based retrospective cohort study. Lancet Reg Health-West Pac. 2021;9:100108. doi: 10.1016/j.lanwpc.2021.100108
   PubMedGoogle Scholar
• Hause AM, Baggs J, Marquez P, et al. Safety monitoring of COVID-19 vaccine booster doses among adults - United States, September 22, 2021-February 6, 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):249–254. doi: 10.15585/mmwr.mm7107e1
   PubMed Web of Science ®Google Scholar
• Klein NP. Rapid cycle analysis to monitor the safety of COVID-19 vaccines in near real-time within the vaccine safety datalink: myocarditis and anaphylaxis. ACIP meeting COVID-19 Vaccines; August 30, 2021; 2021.
   Google Scholar
• Menges D, Ballouz T, Anagnostopoulos A, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: a population-based cohort study. PLoS One. 2021;16(7):e0254523. doi: 10.1371/journal.pone.0254523
   PubMed Web of Science ®Google Scholar
• Forbes. Convert Thai Baht to United States dollar 2023 [cited 2023 Jul 31]. Available from: https://www.forbes.com/advisor/money-transfer/currency-converter/thb-usd/
   Google Scholar
• Marome W, Shaw R. COVID-19 response in Thailand and its implications on future preparedness. Int J Environ Res Public Health. 2021;18(3):1089. doi: 10.3390/ijerph18031089
   PubMed Web of Science ®Google Scholar
• Aggarwal B, Jones PW, Yunus F, et al. Direct healthcare costs associated with management of asthma: comparison of two treatment regimens in Indonesia, Thailand and Vietnam. J Asthma. 2022;59(6):1213–1220. doi: 10.1080/02770903.2021.1903915
   PubMed Web of Science ®Google Scholar
• Wang Y, Luangasanatip N, Pan–Ngum W, et al. Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic. Eur J Health Econ. 2022;24(5):1–14. doi: 10.1007/s10198-022-01505-2
   PubMed Web of Science ®Google Scholar
• Trading Economics. Thailand average monthly wages 2023. Available from: https://tradingeconomics.com/thailand/wages
   Google Scholar
• Centers for Disease Control and Prevention. Ending isolation and precautions for people with COVID-19: interim guidance 2022 [cited 2022 Aug 31]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html
   Google Scholar
• Sirijatuphat R, Suputtamongkol Y, Angkasekwinai N, et al. Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand’s university-based referral hospital. BMC Infect Dis. 2021;21(1):1–10. doi: 10.1186/s12879-021-06081-z
   PubMed Web of Science ®Google Scholar
• Trerayapiwat K, Jinatongthai P, Vathesatogkit P, et al. Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand. Lancet Reg Health-West Pac. 2022;26:100503. doi: 10.1016/j.lanwpc.2022.100503
   PubMedGoogle Scholar
• Sharma D, Aggarwal AK, Downey LE, et al. National healthcare economic evaluation guidelines: a cross-country comparison. PharmacoEconomics-Open. 2021;5:349–364. doi: 10.1007/s41669-020-00250-7
   PubMed Web of Science ®Google Scholar
• World Health Organization. Interim statement on booster doses for COVID-19 vaccination 2021 [ updated 2021 Oct 4; cited 2023 May 5]. Available from: https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination
   Google Scholar
• Intawong K, Chariyalertsak S, Chalom K, et al. Heterologous third and fourth dose vaccine to reduce severity and mortality in COVID-19 patients during delta and omicron predominance: a cohort study in Chiang Mai. Int J Infect Dis. 2022 May 1;130: S135.
   Web of Science ®Google Scholar
• Thye A-K, Tan L-H, Law JWF, et al. COVID-19 booster vaccines administration in different countries. Prog Micobes Mol Biol. 2021;4(1). doi: 10.36877/pmmb.a0000256
   Google Scholar
• Orimo H, Ito H, Suzuki T, et al. Reviewing the definition of “elderly”. Geriatrics Gerontol Int. 2006;6(3):149–158. doi: 10.1111/j.1447-0594.2006.00341.x
   Google Scholar
• United Nations Economic and Social Commission for Asia and the Pacific. Social development and ageing societies. Available from: https://www.unescap.org/our-work/social-development/ageing-societies#:~:text=Older%20persons%2C%20defined%20as%20those,be%2060%20years%20or%20over
   Google Scholar
• Xu Z, Zhang H, Huang Z. A continuous Markov-chain model for the simulation of COVID-19 epidemic dynamics. Biology. 2022;11(2):190. doi: 10.3390/biology11020190
   PubMedGoogle Scholar
• Dehghan Shabani Z, Shahnazi R. Spatial distribution dynamics and prediction of COVID‐19 in Asian countries: spatial Markov chain approach. Reg Sci Policy Pract. 2020;12(6):1005–1025. doi: 10.1111/rsp3.12372
   Web of Science ®Google Scholar
• Lochen A, Anderson RM. Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations. Clin Microbiol Infect. 2021 Oct;27(10):1546–1557. doi: 10.1016/j.cmi.2021.07.002
   Web of Science ®Google Scholar
• Ao D, He X, Hong W, et al. The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB. 1.5 and BQ. 1.1 subvariants. MedComm. 2023;4(2):e239. doi: 10.1002/mco2.239
   PubMedGoogle Scholar